+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Rigel Pharmaceuticals Inc - logo

Rigel Pharmaceuticals is a clinical-stage biotechnology company that focuses on the therapeutic areas of immunology, oncology and immuno-oncology. Rigel’s current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of a variety of diseases. It has been in trials for rheumatoid arthritis, autoimmune thrombocytopenia, lymphoma and others. In addition, Rigel also has two oncology product candidates in development. Founded in 1996, Rigel is headquartered in San Francisco, California.

Peritoneal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Peritoneal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • June 2022
  • 925 Pages
  • Global
From
Psoriasis - Pipeline Review, H2 2020 - Product Thumbnail Image

Psoriasis - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 956 Pages
  • Global
From
Transforming growth factor beta inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Transforming growth factor beta inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 150 Pages
  • Global
From
Thrombocytopenia - Market Insight, Epidemiology And Market Forecast - 2032 - Product Thumbnail Image

Thrombocytopenia - Market Insight, Epidemiology And Market Forecast - 2032

  • Report
  • September 2022
  • 225 Pages
  • Global
From
Rheumatoid Arthritis - Pipeline Review, H2 2020 - Product Thumbnail Image

Rheumatoid Arthritis - Pipeline Review, H2 2020

  • Drug Pipelines
  • July 2020
  • 1191 Pages
  • Global
From
Bile Duct Cancer (Cholangiocarcinoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Bile Duct Cancer (Cholangiocarcinoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 507 Pages
  • Global
From
Fallopian Tube Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Fallopian Tube Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • August 2022
  • 871 Pages
  • Global
From
RIPK1 inhibitor - Pipeline Insights, 2024 - Product Thumbnail Image

RIPK1 inhibitor - Pipeline Insights, 2024

  • Clinical Trials
  • January 2024
  • 50 Pages
  • Global
From
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 1560 Pages
  • Global
From
North America Small Molecule Drug Delivery Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Therapeutic Area; Process/Phase, and Country - Product Thumbnail Image

North America Small Molecule Drug Delivery Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Therapeutic Area; Process/Phase, and Country

  • Report
  • August 2020
  • 130 Pages
  • North America
From
Kidney Transplant Rejection - Pipeline Review, H2 2020 - Product Thumbnail Image

Kidney Transplant Rejection - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 191 Pages
  • Global
From
Interleukin 1 Receptor Associated Kinase 4 Global Market Insights 2022, Analysis and Forecast to 2027, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Interleukin 1 Receptor Associated Kinase 4 Global Market Insights 2022, Analysis and Forecast to 2027, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • May 2022
  • 86 Pages
  • Global
From
Interleukin-1 (IL-1) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Interleukin-1 (IL-1) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 120 Pages
  • Global
From
Cardiovascular Collaboration and Licensing Deals 2016-2024 - Product Thumbnail Image

Cardiovascular Collaboration and Licensing Deals 2016-2024

  • Report
  • April 2024
  • 300 Pages
  • Global
From
IgA Nephropathy Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments - Product Thumbnail Image

IgA Nephropathy Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments

  • Report
  • May 2018
  • 97 Pages
  • Global
From
Idiopathic Thrombocytopenic Purpura - Pipeline Insight, 2024 - Product Thumbnail Image

Idiopathic Thrombocytopenic Purpura - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Rare Kidney Diseases Market by Target Indications, Type of Molecule, Route of Administration and Key Geographies: Industry Trends and Global Forecast, 2022-2035 - Product Thumbnail Image

Rare Kidney Diseases Market by Target Indications, Type of Molecule, Route of Administration and Key Geographies: Industry Trends and Global Forecast, 2022-2035

  • Report
  • October 2022
  • 95 Pages
  • Global
From
Distribution Deals in Pharmaceuticals and Biotechnology 2016 to 2024 - Product Thumbnail Image

Distribution Deals in Pharmaceuticals and Biotechnology 2016 to 2024

  • Report
  • March 2024
  • 500 Pages
  • Global
From
Idiopathic Thrombocytopenic Purpura - Pipeline Review, H2 2020 - Product Thumbnail Image

Idiopathic Thrombocytopenic Purpura - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 180 Pages
  • Global
From
Manufacturing and Supply Deals in Pharmaceuticals and Biotechnology 2019-2024 - Product Thumbnail Image

Manufacturing and Supply Deals in Pharmaceuticals and Biotechnology 2019-2024

  • Report
  • March 2024
  • 650 Pages
  • Global
From
Loading Indicator